SHANK3 and premenstrual tension: After accounting for the mechanism of deletion and the size of the genetic loss, individuals with PMS occupy a broad spectrum of disease severity, yet the most common treatment approach is the reappropriation of existing pharmaceuticals that primarily treat the neurobehavioral symptoms attributed to the loss of SHANK3. The preference for this approach is most likely a consequence of their general safety and prior success in navigating the BBB and other obstacles to drug delivery.